🇺🇸 FDA
Pipeline program

Ofatumumab

COMB157G2402

Approved mab completed

Quick answer

Ofatumumab for Relapsing Multiple Sclerosis is a Approved program (mab) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Pharmaceuticals
Indication
Relapsing Multiple Sclerosis
Phase
Approved
Modality
mab
Status
completed

Clinical trials